TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
The pathological deposition of the transactive response DNA-binding protein of 43 kDa occurs in the majority (∼97%) of amyotrophic lateral sclerosis and in around 45% of frontotemporal lobar degeneration cases. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration clinically overlap, presenting a continuum of phenotypes. Both amyotrophic lateral sclerosis and frontotemporal lobar degeneration lack treatments capable of interfering with the underlying pathological process and early detection of transactive response DNA-binding protein of 43 kDa pathology would facilitate the development of disease-modifying drugs. The real-time quaking-induced conversion reaction showed the ability to detect prions in several peripheral tissues of patients with different forms of prion and prion-like diseases. Despite transactive response DNA-binding protein of 43 kDa displays prion-like properties, to date the real-time quaking-induced conversion reaction technology has not yet been adapted to this protein. The aim of this study was to adapt the real-time quaking-induced conversion reaction technique for the transactive response DNA-binding protein of 43 kDa substrate and to exploit the intrinsic ability of this technology to amplify minute amount of mis-folded proteins for the detection of pathological transactive response DNA-binding protein of 43 kDa species in the cerebrospinal fluid of amyotrophic lateral sclerosis and frontotemporal lobar degeneration patients. We first optimized the technique with synthetic transactive response DNA-binding protein of 43 kDa–pre-formed aggregates and with autopsy-verified brain homogenate samples and subsequently analysed CSF samples from amyotrophic lateral sclerosis and frontotemporal lobar degeneration patients and controls. Transactive response DNA-binding protein of 43 kDa real-time quaking-induced conversion reaction was able to detect as little as 15 pg of transactive response DNA-binding protein of 43 kDa aggregates, discriminating between a cohort of patients affected by amyotrophic lateral sclerosis and frontotemporal lobar degeneration and age-matched controls with a total sensitivity of 94% and a specificity of 85%. Our data give a proof-of-concept that transactive response DNA-binding protein of 43 kDa is a suitable substrate for the real-time quaking-induced conversion reaction. Transactive response DNA-binding protein of 43 kDa real-time quaking-induced conversion reaction could be an innovative and useful tool for diagnosis and drug development in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The cerebrospinal fluid detection of transactive response DNA-binding protein of 43 kDa pathological aggregates may be exploited as a disease biomarker for amyotrophic lateral sclerosis and frontotemporal lobar degeneration patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study using real time quaking‐induced conversion assay, a test based on the amplification of misfolded proteins and used for detection of prion proteins, showed in vitro TDP‐43 aggregate formation in CSF.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [100]
In the citing paper
“In a recent proof‐of‐concept small clinical study this assay discriminated FTD and ALS patients from controls with 94% sensitivity and 85% specificity.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [100]
In the citing paper
“Diagnosis is typically delayed for up to 6 years. 100”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 8×
“Subsequent studies showed abnormal accumulation of TDP-43 in neurodegenerative disorders other than FTLD and ALS, collectively named TDP-43 proteinopathies (Nonaka and Hasegawa, 2018).”
BackgroundInfluentialEl Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“In fact, like amyloid b-deposition in AD (Bateman et al., 2012), it is”
BackgroundAppelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.093 · Cited by 2,732
Qualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Cited by
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS
(2024) · doi:10.1038/s41591-024-02937-4 · Cited by 217
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00341-0 · Cited by 218
Designing the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Frontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 145
Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design
Toledo, J. B., Ruiz, C. A., Weil, R. S., Ferreira, D., Rodriguez‐Porcel, F. E., Pilotto, A., Wyman‐Chick, K. A., Grothe, M. J., Kane, J. P. M., Taylor, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12814 · Cited by 121
Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43
Tarutani, A., Adachi, T., Akatsu, H., Hashizume, Y., Hasegawa, K., Saito, Y., Robinson, A., Mann, D. M. A., Yoshida, M., Murayama, S., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02426-3 · Cited by 78
Candelise, N., Scaricamazza, S., Salvatori, I., Ferri, A., Valle, C., Manganelli, V., Garofalo, T., Sorice, M., & Misasi, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116016 · Cited by 78
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 87
Zetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 61
Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia
Benussi, A., Alberici, A., Samra, K., Russell, L. L., Greaves, C. V., Bocchetta, M., Ducharme, S., Finger, E. C., Fumagalli, G., Galimberti, D., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12485 · Cited by 67
Self-citationFluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis
Pasetto, L., Callegaro, S., Corbelli, A., Fiordaliso, F., Ferrara, D., Brunelli, L., Sestito, G., Pastorelli, R., Bianchi, E., Cretich, M., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00470-3 · Cited by 62
Self-citationMethods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias
Teunissen, C. E., Kimble, L. E., Bayoumy, S., Bolsewig, K., Burtscher, F., Coppens, S., Das, S., Gogishvili, D., Gomes, B. F., José, N. G. D. S., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100629 · Cited by 63
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
α-Synuclein seed amplification technology for Parkinson’s disease and related synucleinopathies
Soto, C. A. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.01.007 · Cited by 54
Mizielinska, S., Hautbergue, G. M., Gendron, T. F., van Blitterswijk, M., Hardiman, O. M., Ravits, J., Isaacs, A. M., & Rademakers, R. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00026-2 · Cited by 59
RNA-binding proteins in ALS and FTD: from pathogenic mechanisms to therapeutic insights
Rummens, J., & Cruz, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00851-y · Cited by 64
Neurodegenerative disease of the brain: a survey of interdisciplinary approaches
Davenport, F., Gallacher, J., Kourtzi, Z., Koychev, I. G., Matthews, P. M., Oxtoby, N. P., Parkes, L. M., Priesemann, V., Rowe, J. B., Smye, S. W., et al. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0406 · Cited by 55
Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy
Balendra, R., Sreedharan, J., Hallegger, M., Luisier, R., Lashuel, H. A., Gregory, J. M., & Patani, R. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00109-7 · Cited by 66
Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease
Mok, T. H., Nihat, A., Majbour, N. K., Sequeira, D., Holm-Mercer, L., Coysh, T., Darwent, L., Batchelor, M., Groveman, B. R., Orr, C. D., et al. (2023) · Brain · doi:10.1093/brain/awad101 · Cited by 51
Real-Time Quaking- Induced Conversion Assays for Prion Diseases, Synucleinopathies, and Tauopathies
Vascellari, S., Orru, C. D., & Caughey, B. W. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.853050 · Cited by 48
TDP-43 Proteinopathy Specific Biomarker Development
Cordts, I., Wachinger, A., Scialò, C., Lingor, P., Polymenidou, M., Buratti, E., & Feneberg, E. (2023) · Cells · doi:10.3390/cells12040597 · Cited by 55
Self-citationThe Future of Seed Amplification Assays and Clinical Trials
Coysh, T., & Mead, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.872629 · Cited by 45
Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias
Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 59
Biomarkers for amyotrophic lateral sclerosis
Witzel, S., Mayer, K., & Oeckl, P. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001094 · Cited by 46
Shahim, P., & Zetterberg, H. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.10.010 · Cited by 39
Bergström, S., Öijerstedt, L., Remnestål, J., Olofsson, J., Ullgren, A., Seelaar, H., van Swieten, J. C., Synofzik, M., Sanchez-Valle, R., Moreno, F., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00499-4 · Cited by 36
Self-citationGibson, L. L., Ruiz, C. A., Chong, J. R., Ballard, C. G., & Aarsland, D. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001173 · Cited by 38
ADNI Biomarker Core: A review of progress since 2004 and future challenges
Shaw, L. M. J., Korecka, M., Lee, E. B., Cousins, K. A. Q., Vanderstichele, H., Schindler, S. E., Tosun, D., DeMarco, M. L., Brylska, M., Wan, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14264 · Cited by 47
Fontana, E., Bongianni, M., Benussi, A., Bronzato, E., Scialò, C., Sacchetto, L., Cagnin, A., Castriciano, S., Buratti, E., Gardoni, F., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13541 · Cited by 38
Self-citationSeeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures
Scialò, C., Zhong, W., Jagannath, S., Wilkins, O. G., Caredio, D., Hruška-Plocháň, M., Lurati, F., Peter, M., Cecco, E. D., Celauro, L., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.03.008 · Cited by 50
Self-citationFTLD-TDP assemblies seed neoaggregates with subtype-specific features via a prion-like cascade
Rossi, P. D., Lewis, A. J., Furrer, J., Vos, L. D., Demeter, T., Zbinden, A., Zhong, W., Wiersma, V. I., Scialò, C., Weber, J., et al. (2021) · EMBO Reports · doi:10.15252/embr.202153877 · Cited by 34
Self-citationThe Cellular Prion Protein Increases the Uptake and Toxicity of TDP-43 Fibrils
Scialò, C., Celauro, L., Zattoni, M., Tran, T. H., Bistaffa, E., Moda, F., Kammerer, R., Buratti, E., & Legname, G. (2021) · Viruses · doi:10.3390/v13081625 · Cited by 35
Self-citationAfroz, T., Chevalier, E., Audrain, M., Dumayne, C., Ziehm, T., Moser, R., Egesipe, A.-L., Mottier, L., Ratnam, M., Neumann, M., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106050 · Cited by 39
Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder
Marchi, F. D., Franjkic, T., Schito, P., Russo, T., Nimac, J., Chami, A. A., Mele, A., Vidatic, L., Križ, J., Julien, J., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061599 · Cited by 31
Self-citationThe blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 32
Tosun, D., Yardibi, O., Benzinger, T. L. S., Kukull, W. A., Masters, C. L., Perrin, R. J., Weiner, M. W., Simen, A. A., Schwarz, A. J., & Initiative, A. D. N. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13447 · Cited by 32
Biomarkers in frontotemporal dementia: Current landscape and future directions
Gifford, A., Praschan, N. C., Newhouse, A. L., & Chemali, Z. N. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100065 · Cited by 33
Solje, E., Benussi, A., Buratti, E., Remes, A. M., Haapasalo, A., & Borroni, B. (2021) · Diagnostics · doi:10.3390/diagnostics11050788 · Cited by 29
Self-citationSeed amplification and RT-QuIC assays to investigate protein seed structures and strains
Standke, H. G., & Kraus, A. (2022) · Cell and Tissue Research · doi:10.1007/s00441-022-03595-z · Cited by 27
Recent Advances in Frontotemporal Dementia
Tartaglia, M. C., & Mackenzie, I. R. (2022) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2022.69 · Cited by 27
Teipel, S. J., & Grothe, M. J. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106070 · Cited by 23
Giampietri, L., Belli, E., Beatino, M. F., Giannoni, S., Palermo, G., Campese, N., Tognoni, G., Siciliano, G., Ceravolo, R., Luca, C. D., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040796 · Cited by 25
Sheth, U., Öijerstedt, L., Heckman, M. G., White, L. J., Heuer, H. W., Lario Lago, A., Forsberg, L. K., Faber, K. M., Foroud, T. M., Rademakers, R., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00821-4 · Cited by 20
“…of tau or TDP-43-related biomarkers are underway, including measures of cryptic peptides as surrogate markers of TDP-43 pathology [56–58], and emerging methods to measure tau and TDP-43 in plasma extracellular vesicles [59], or to detect tau or TDP-43 aggregates in cerebrospinal fluid [60, 61].”
Toward a biological definition of neuronal and glial synucleinopathies
Soto, C. A., Mollenhauer, B., Hansson, O., Kang, U. J., Alcalay, R. N., Standaert, D. G., Trenkwalder, C., MAREK, K. L., Galasko, D. R., & Poston, K. L. (2025) · Nature Medicine · doi:10.1038/s41591-024-03469-7 · Cited by 29
Refining the clinical diagnosis of Parkinson's disease
Mulroy, E., Erro, R., Bhatia, K. P., & Hallett, M. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106041 · Cited by 28
Fluid biomarkers for neurodegenerative diseases: a comprehensive update
Valletta, M., Briel, N., Yuksekel, I., Barboure, M. C., Coward, A. R., Houwer, J. F. H. D., Fawad, A., González-Mayoral, A., Iaccarino, G., Martínez‐Dubarbie, F., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01919-z · Cited by 26
Frontotemporal dementia. How to deal with its diagnostic complexity?
Antonioni, A., Raho, E. M., Granieri, E., & Koch, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2461758 · Cited by 25
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids
Torrini, F., Gil-García, M., Cardellini, J., Frigerio, R., Basso, M., Gori, A., & Arosio, P. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.006 · Cited by 21
Mielke, J. K., Klingeborn, M., Schultz, E. P., Markham, E. L., Reese, E. D., Alam, P., Mackenzie, I. R., Ly, C. V., Caughey, B. W., Cashman, N. R., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02752-8 · Cited by 20
Reyes‐Leiva, D., Dols‐Icardo, O., Sirisi, S., Cortés‐Vicente, E., Turón‐Sans, J., de Luna, N., Blesa, R., Belbin, O., Montal, V., Alcolea, D. A., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.750543 · Cited by 19
Importin α/β and the tug of war to keep TDP‐43 in solution: quo vadis?
Doll, S. G., & Cingolani, G. (2022) · BioEssays · doi:10.1002/bies.202200181 · Cited by 17
The unique neuropathological vulnerability of the human brain to aging
Ferrer, I. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101916 · Cited by 18
Dilcher, R., Malpas, C. B., O'Brien, T. J., & Vivash, L. E. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221171 · Cited by 14
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF
Audrain, M., Egesipe, A.-L., Tentillier, N., Font, L., Ratnam, M., Mottier, L., Clavel, M., Roux-Bourdieu, M. L., Fenyi, A., Ollier, R., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad306 · Cited by 13
Clark, D. G. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001506 · Cited by 16
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis
Vizziello, M., Dellarole, I. L., Ciullini, A., Pascuzzo, R., Lombardo, A., Bellandi, F., Celauro, L., Battipaglia, C., Ciusani, E., Rizzo, A., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00833-0 · Cited by 13
Self-citationPrion-like Spreading of Disease in TDP-43 Proteinopathies
Pongrácová, E., Buratti, E., & Romano, M. (2024) · Brain Sciences · doi:10.3390/brainsci14111132 · Cited by 19
Self-citationMoudjou, M., Castille, J., Passet, B., Herzog, L., Reine, F., Vilotte, J.-L., Rézaei, H., Béringue, V., & Igel‐Egalon, A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.591024 · Cited by 16
Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer’s Disease
Bistaffa, E., Tagliavini, F., Matteini, P., & Moda, F. (2020) · Brain Sciences · doi:10.3390/brainsci10110815 · Cited by 12
Self-citationIvanova, M. I., Rosa, C. L., & Ramamoorthy, A. (2026) · Protein Science · doi:10.1002/pro.70525 · Cited by 11
Iwatsubo, T., Sperling, R. A., Algeciras‐Schimnich, A., Arai, H., Barron, A. M., Benzinger, T. L. S., Carrillo, M. C., Chen, C., Choi, S. H., Fontana, I. C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70536 · Cited by 13
Frontotemporal dementia as a consequence of GRN mutations: From disease cause to models to therapies
Salzano, S., Bertasini, C., Haghighi, S. T., Lundkvist, J., Wahlberg, L. U., Chiamulera, C., Vattemi, G. N. A., Gardoni, F., & Paolone, G. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107957 · Cited by 16
Detection of TDP‐43 seeds in CSF of presymptomatic and symptomatic genetic FTD/ALS
Dellarole, I. L., Aprea, V., Catania, M., Battipaglia, C., Romeo, A., Villa, C., Burato, A., Celauro, L., Bella, E. D., Riva, N., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70989 · Cited by 9
Self-citationHaußmann, R., Homeyer, P., Brandt, M. D., & Donix, M. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01339-6 · Cited by 11
Defining the presymptomatic phase of frontotemporal dementia
Russell, L. L., & Rohrer, J. D. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001174 · Cited by 10
Teipel, S. J., Grothe, M. J., & Initiative, A. D. N. (2022) · European Journal of Neurology · doi:10.1111/ene.15270 · Cited by 9
Campese, N., Beatino, M. F., Gamba, C. D., Belli, E., Giampietri, L., Prete, E. D., Galgani, A., Vergallo, A., Siciliano, G., Ceravolo, R., et al. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1965879 · Cited by 11
Picard, F., Nonaka, T., Belotti, E., Osseni, A., Errazuriz-Cerda, E., Jost-Mousseau, C., Bernard, E., Conjard‐Duplany, A., Bohl, D., Hasegawa, M., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05589-w · Cited by 9
Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies—Current View
Jellinger, K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167674 · Cited by 8
Neurochemical biomarkers of amyotrophic lateral sclerosis: recent developments
Verde, F. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001411 · Cited by 9
Preclinical and Prodromal Frontotemporal Dementia: Challenges and Opportunities
Palacino, F., Manganotti, P., & Benussi, A. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5040052 · Cited by 7
Self-citationLiquid–liquid phase separation in neurodegenerative diseases
Haider, R., Boyko, S., & Surewicz, W. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823967-4.00018-x · Cited by 8
Different Chronic Stress Paradigms Converge on Endogenous TDP43 Cleavage and Aggregation
Candelise, N., Caissutti, D., Zenuni, H., Nesci, V., Scaricamazza, S., Salvatori, I., Spinello, Z., Mattei, V., Garofalo, T., Ferri, A., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03455-z · Cited by 8
Caughey, B. W., Artikis, E., Shoup, D. W., Orru, C. D., Alam, P., Parveen, S., King, S., Soukup, J., Hughson, A. G., & Priola, S. A. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-25 · Cited by 9
AI-QuIC machine learning for automated detection of misfolded proteins in seed amplification assays
Howey, K. D., Li, M., Christenson, P. R., Larsen, P. A., & Oh, S. (2025) · npj Biosensing · doi:10.1038/s44328-025-00035-0 · Cited by 6
Eldik, L. J. V., Siemers, E., Collins, E. C., Gold, M., Henley, D. B., Johannsen, P., Möbius, H. J., Shulman, M. B., Zhou, J., Carrillo, M. C., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70014 · Cited by 7
TDP ‐43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models
Pir, G. J., Buddenkotte, J., Alam, M. A., Own, A. M., Eck, R. J., Kraemer, B. C., Mandelkow�, E., & Steinhoff, M. S. (2025) · FEBS Journal · doi:10.1111/febs.70239 · Cited by 6
Honey, M. I. J., Hok‐A‐Hin, Y. S., Thijssen, E. H., Cousins, K. A. Q., van der Weijden, B., Veld, L. I. ‘., Stoops, E., de Boer, S. C. M., Duits, F. H., Houwer, J. F. H. D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04341-6 · Cited by 8
Pelagotti, V., Plantone, D., D’Amico, F., Raffa, S., Mattioli, P., Orso, B., Losa, M., Manco, C., Righi, D., Arnaldi, D., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107014 · Cited by 7
Montalesi, E., Caissutti, D., Moliterni, C., Ferrante, A., Pepponi, R., Garofalo, T., Sorice, M., Misasi, R., & Candelise, N. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05884-6 · Cited by 5
Co-aggregation of annexin A11 and TDP-43 in FTLD/MND with primary lateral sclerosis phenotype
Tarutani, A., Nonaka, T., Ohtani, R., Imai, K., Ito, Y., Tsuji, H., Mochizuki, A., Tamaoka, A., Arai, T., Robinson, A., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02210-w · Cited by 5
Sakamoto, S., Riku, Y., Nomura, T. K., Kimura, A., Yamahara, N., Ohuchi, K., Yoshida, M., Iwasaki, Y., Shimohata, T., Inden, M., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00444-7 · Cited by 4
Lazarev, V. F., Alhasan, B. A., Guzhova, I. V., & Margulis, B. A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1593122 · Cited by 5
Dellarole, I. L., Lombardo, A., Ciullini, A., Cazzaniga, F. A., Domina, R., Bacınoğlu, M. B., & Moda, F. (2025) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-97055-9_13 · Cited by 3
Self-citationQuICSeedR: an R package for analyzing fluorophore-assisted seed amplification assay data
Li, M., Bryant, D. N., Gresh, S., Milstein, M. S., Christenson, P. R., Lichtenberg, S. S., Larsen, P. A., & Oh, S. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae752 · Cited by 4
The prion-like effect and prion-like protein targeting strategy in amyotrophic lateral sclerosis
Wenzhi, Y., Xiangyi, L., & Dongsheng, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34963 · Cited by 3
Digital seed amplification assay for TDP‐43 aggregate quantification in CSF
Borberg, E., Swank, Z., Gilboa, T., Shearer, L. A. W., Melkonian, A. V., Rolando, J. C., Walt, D. R., & Stern, A. M. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71272 · Cited by 4
Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism
Pinto, M. J. A., Cordero, I. R. G., Dorman, G. S., Mizraji, G., Anastassiadis, C., Gershanik, O. S., & Couto, B. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01488-0 · Cited by 4
Multimodal strategies for diagnosis, stratification, and therapeutic monitoring in ALS
López‐Blanch, R., Oriol‐Caballo, M., Estrela, J. M., & Obrador, E. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106727 · Cited by 3
Les marqueurs biologiques des démences fronto-temporales
Escal, J., & Fourier, A. (2021) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(21)00193-3 · Cited by 3
Protein Misfolding Cyclic Amplification
Moda, F., Pritzkow, S., & Soto, C. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-20565-1_31 · Cited by 1
Self-citationMalerba, F., Florio, R., Arisi, I., Zecca, C., Dell’Abate, M. T., Logroscino, G., & Cattaneo, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1298307 · Cited by 3
TDP-43 as a Fluid Biomarker in Amyotrophic Lateral Sclerosis
Choi, S. (2024) · Journal of Electrodiagnosis and Neuromuscular Diseases · doi:10.18214/jend.2024.00080 · Cited by 1
Application of protein misfolding amplification techniques in prion diseases
Liu, R., Chen, Z., Wang, Y., & Wu, L. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.18 · Cited by 2
Otero‐Jimenez, M., Wojewska, M. J., Jogaudaite, S., Miller, D. E., Gray‐Rodriguez, S., Geoghegan, G., Abelleira, L. E., Viney, T. J., Sárkány, B., Gveric, D. O., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01111-y · Cited by 3
Cazzaniga, F. A., Bufano, G., Bellandi, F., Bacınoğlu, M. B., & Moda, F. (2025) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-97055-9_12 · Cited by 1
Self-citationAlpha-synuclein seed amplification assays differentiate synucleinopathies
Dai, W., Lin, H., Mao, H., Kuang, Y., Xu, P., & Li, H. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2663033 · Cited by 2
Biomarcatori periferici nelle malattie neurodegenerative: una rassegna sui seed amplification assays
Cazzaniga, F. A., & Moda, F. (2026) · Biochimica Clinica · doi:10.23736/s0393-0564.26.00174-3 · Cited by 1
Self-citation
Metadata
- Authors
- Scialò, C., Tran, T. H., Salzano, G., Novi, G., Caponnetto, C., Chiò, A., Calvo, A., Canosa, A., Moda, F., Caroppo, P., Silani, V., Ticozzi, N., Ratti, A., Borroni, B., Benussi, L., Ghidoni, R., Furlanis, G., Manganotti, P., Senigagliesi, B., Parisse, P., Brasselet, R., Buratti, E., & Legname, G.
- Affiliations
- Scuola Internazionale Superiore di Studi Avanzati (IT)
- Ospedale Policlinico San Martino (IT)
- University of Turin (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- University of Milan (IT)
- University of Brescia (IT)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- University of Trieste (IT)
- Elettra-Sincrotrone Trieste S.C.p.A. (IT)
- International Centre for Genetic Engineering and Biotechnology (IT)
- Corresponding author
- Legname, Giuseppe
- ORCID
- Scialò, Carlo
- Tran, Thanh Hoa
- Salzano, Giulia
- Novi, Giovanni
- Caponnetto, Claudia
- Chiò, Adriano
- Calvo, Andrea
- Canosa, Antonio
- Moda, Fabio
- Caroppo, Paola
- Silani, Vincenzo
- Ticozzi, Nicola
- Ratti, Antonia
- Borroni, Barbara
- Benussi, Luisa
- Ghidoni, Roberta
- Furlanis, Giovanni
- Manganotti, Paolo
- Senigagliesi, Beatrice
- Parisse, Pietro
- Brasselet, Romain
- Buratti, Emanuele
- Legname, Giuseppe
- Venue
- Brain Communications
- Publisher
- Oxford University Press (OUP)
- Published
- 2020
- Volume
- 2
- Issue
- 2
- Pages
- fcaa142-fcaa142
- ISSN
- 2632-1297 (ISSN-L)
- PMC
- PMC7566418
- OpenAlex
- W3086212084
- Cited by
- 123
- References
- 56
- Citations by year
- 2026: 22 · 2025: 35 · 2024: 14 · 2023: 19 · 2022: 19 · 2021: 12 · 2020: 2
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Communications (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- SDL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Funders
- Scuola Internazionale Superiore di Studi Avanzati intramural
- Italian Ministry of Health (GR-2013-02355724, GR-2013-02355764)
- Frontotemporal Degeneration Susan Marcus Memorial
- Clinical Research Pilot
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- TDP-43, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, cerebrospinal fluid biomarkers, seeding activity, prion-like proteins, protein misfolding, disease diagnosis, sensitivity and specificity, brain homogenate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.